Envoy Medical Inc. (Class A) (COCH) Next Earnings Date & Expected ±12.5% Move

COCH carries an RQD Score of 35 out of 100 and a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are scored as follows:

• Fundamental Cash Engine: 7 / 20. The source cites ROIC of -35% and an FCF yield of 0%. For a prospective investor, this indicates the business is not currently generating a return on invested capital or free cash flow to offset its operating losses.
• Whale 13F Flow: 7 / 20. The pillar reflects institutional accumulation and options positioning.
• Insider Conviction: 5 / 20. This is the lowest pillar and reflects SEC Form 4 and Congressional PTR cluster flow. The individual transactions are not itemized in the source data.
• Macro Regime Fit: 8 / 20. Beta is 1.0, and the pillar also reflects sector sensitivity. A beta of 1.0 means the stock is modeled to move in line with the broad market, offering no defensive cushion.
• Forensic Balance Sheet: 8 / 20..5, the Piotroski F-Score is 2 out of 9, and Debt/Equity is 0.5. A low Piotroski score points to weak financial-health signals across multiple tests.

Taken together, the pillar scores point to a company with negative economics, weak forensic signals, and limited evidence of institutional or insider conviction. Upside drivers would need to come from a sustained change in operating results, which the historical financials do not yet show. The valuation tradeoff is that the market is pricing a small-cap, loss-making issuer, and the rating frames the risk as balance-sheet and flow vulnerability rather than a near-term earnings recovery. This analysis is educational and is not personalized financial advice.

Envoy Medical Inc. (Class A) (COCH) is a NASDAQ-listed issuer in the Health Care sector, classified under the Industrial Specialties industry..1B.

Revenue has been minimal across the three reported years ($0.3M, then $0.2M in each of the two subsequent years), while operating losses and free-cash-flow burn have persisted. Per the market data, gross margin is -30%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2 out of 9, .5 cited in the forensic pillar.

• 🐂 Primary Bull Case: Lake Street initiated coverage at a buy rating on the company's cochlear device. With Fundamental Cash Engine at 7/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 8/20, sustained execution supports upside toward the top of the $3.63 – $9.54 52-week range.
• 🐻 Primary Bear Case: Negative ROIC of -35% and 0% FCF yield with a Piotroski F-Score of 2 out of 9 show weak cash generation and balance-sheet signals. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The sector and industry classification (Health Care / Industrial Specialties) is the only structural context provided.

• Key Question #1: What are the reported cash and debt balances, which are listed as N/A across all periods?
• Key Question #2: What is the company's path to positive operating cash flow, and what funding is available to sustain the current burn rate?
• Key Question #3: What would the post-reverse-split share count and per-share metrics look like, and how will they affect EPS and market-cap comparisons?